• Mervyn Singer.
• University College London, London, UK. m.singer@ucl.ac.uk
• Curr Opin Pulm Med. 2013 May 1; 19 (3): 305-9.

Purpose Of ReviewThis review discusses the current developments in biomarkers for sepsis.Recent FindingsWith quantum leaps in technology, an array of biomarkers will become available within the next decade as point-of-care tools that will likely revolutionize the management of sepsis. These markers will facilitate early and accurate diagnosis, faster recognition of impending organ dysfunction, optimal selection and titration of appropriate therapies, and more reliable prognostication of risk and outcome. These diagnostics will also enable an improved characterization of the biological phenotype underlying sepsis and thus a better appreciation of the condition.SummaryThe potential for novel biomarkers in sepsis will need to be properly realized with considerable funding, academic-industry collaborations, appropriate investigations and validation in heterogenous populations, but these developments do hold the capacity to transform patient care and outcomes.

12 keywords...

hide…